Log In
Print
BCIQ
Print
Print this Print this
 

Subcutaneous Actemra, Subcutaneous RoActemra, tocilizumab

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSubcutaneous formulation of a humanized mAb against IL-6 receptor
Molecular Target Interleukin-6 (IL-6) receptor (CD126)
Mechanism of ActionInterleukin-6 (IL-6) receptor (CD126) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentApproved
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat moderate to severe active rheumatoid arthritis (RA); Treat rheumatoid arthritis (RA)
Regulatory Designation

U.S. - Standard Review (Treat moderate to severe active rheumatoid arthritis (RA));
EU - Standard Review (Treat moderate to severe active rheumatoid arthritis (RA))

Partner

Chugai Pharmaceutical Co. Ltd.; Genentech Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today